NASDAQ:SMMT

Summit Therapeutics Stock Forecast, Price & News

$5.36
-0.24 (-4.29 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.36
Now: $5.36
$5.59
50-Day Range
$5.24
MA: $5.98
$6.97
52-Week Range
$2.90
Now: $5.36
$12.30
Volume140,515 shs
Average Volume207,734 shs
Market Capitalization$444.43 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. Summit Therapeutics Inc. was founded in 2003 and is based in Cambridge, Massachusetts.
Summit Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SMMT
CUSIPN/A
Phone44-12-3544-3939
Employees70
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$56.50 million
Book Value$0.50 per share

Profitability

Net Income$9.99 million
Net Margins-933.62%

Miscellaneous

Market Cap$444.43 million
Next Earnings DateN/A
OptionableOptionable

Headlines

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.5%
April 6, 2021 |  americanbankingnews.com
Summit Therapeutics Announces Rights Offering
March 26, 2021 |  finance.yahoo.com
Summit Therapeutics Plc Share Chat
February 6, 2021 |  lse.co.uk
Summit Therapeutics Inc.
January 9, 2021 |  barrons.com
Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher
December 16, 2020 |  finance.yahoo.com
Why Summit Therapeutics Shares Climbed 12.9% Today
September 12, 2020 |  sg.finance.yahoo.com
Summit Therapeutics plc (SMMT)
August 4, 2020 |  ca.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

0.64 out of 5 stars

Medical Sector

1323rd out of 2,025 stocks

Pharmaceutical Preparations Industry

584th out of 772 stocks

Analyst Opinion: 1.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$5.36
-0.24 (-4.29 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

Is Summit Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Summit Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View analyst ratings for Summit Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Summit Therapeutics?

Wall Street analysts have given Summit Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Summit Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) released its quarterly earnings results on Wednesday, March, 17th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The business earned $4.55 million during the quarter, compared to analyst estimates of $4.53 million. Summit Therapeutics had a negative net margin of 933.62% and a negative trailing twelve-month return on equity of 100.94%.
View Summit Therapeutics' earnings history
.

How has Summit Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Summit Therapeutics' stock was trading at $1.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SMMT stock has increased by 183.6% and is now trading at $5.36.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SMMT?

1 equities research analysts have issued 12 month target prices for Summit Therapeutics' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Summit Therapeutics' share price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 25.4%.
View analysts' price targets for Summit Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the following people:
  • Mr. Robert W. Duggan, Exec. Chairman & CEO (Age 77)
  • Prof. Dame Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 71)
  • Mr. Michael Paul Donaldson, Chief Financial Officer
  • Dr. Mahkam Zanganeh M.B.A., D.D.S., MBA, COO & Director (Age 51)
  • Dr. David Jonathan Powell, Chief Scientific Officer (Age 51)
  • Ms. Michelle Avery, Director of Investor Relations
  • Dave Gancarz, VP of Investor Relations & Corp. Strategy
  • Ms. Anna Diaz Triola MBA, VP of Marketing
  • Dr. Jonathon Tinsley, Chief Scientific Officer of DMD (Age 62)
  • Dr. Anne Heatherington, Head of Clinical Devel. and Quantitative Sciences

Who are some of Summit Therapeutics' key competitors?

What other stocks do shareholders of Summit Therapeutics own?

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

How do I buy shares of Summit Therapeutics?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $5.36.

How much money does Summit Therapeutics make?

Summit Therapeutics has a market capitalization of $444.43 million and generates $56.50 million in revenue each year.

How many employees does Summit Therapeutics have?

Summit Therapeutics employs 70 workers across the globe.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is www.summitplc.com.

Where are Summit Therapeutics' headquarters?

Summit Therapeutics is headquartered at 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.